» Articles » PMID: 18641340

Lipoproteins of Listeria Monocytogenes Are Critical for Virulence and TLR2-mediated Immune Activation

Overview
Journal J Immunol
Date 2008 Jul 22
PMID 18641340
Citations 49
Authors
Affiliations
Soon will be listed here.
Abstract

Numerous cell surface components of Listeria influence and regulate innate immune recognition and virulence. Here, we demonstrate that lipidation of prelipoproteins in Listeria monocytogenes is required to promote NF-kappaB activation via TLR2. In HeLa cells transiently expressing TLR2, L. monocytogenes and Listeria innocua mutants lacking the prolipoprotein diacylglyceryl transferase (lgt) gene are unable to induce TLR2-dependent activation of NF-kappaB, a property intrinsic to their isogenic parental strains. TLR2-dependent immune recognition is directed to secreted, soluble lipoproteins as evidenced by the sensitivity of the response to lipoprotein lipase. Studies of bone marrow-derived macrophages of C57BL/6 wild-type and TLR2-deficient mice infected with wild-type and lgt mutant strains indicate that the absence of host TLR2 receptor signaling has consequences similar to those of the absence of the bacterial TLR2 ligand, i.e., a delay in cellular immune responses directed toward the bacterium. Infection studies with the wild-type and TLR2(-/-) mice indicated attenuation of the lgt deletion mutant in both mouse strains, implying multiple roles of lipoproteins during infection. Further characterization of the Delta lgt mutant indicated that it is impaired for both invasion and intracellular survival and exhibits increased susceptibility to cationic peptides. Our studies identify lipoproteins as the immunologically active ligand of TLR2 and assign a critical role for this receptor in the recognition of these bacteria during infection, but they also reveal the overall importance of the lipoproteins for the pathogenicity of Listeria.

Citing Articles

Cytosolic bacterial pathogens activate TLR pathways in tumors that synergistically enhance STING agonist cancer therapies.

Danielson M, Nicolai C, Vo T, Wolf N, Burke T iScience. 2024; 27(12):111385.

PMID: 39669426 PMC: 11635009. DOI: 10.1016/j.isci.2024.111385.


Targeting host-specific metabolic pathways-opportunities and challenges for anti-infective therapy.

Konaklieva M, Plotkin B Front Mol Biosci. 2024; 11:1338567.

PMID: 38455763 PMC: 10918472. DOI: 10.3389/fmolb.2024.1338567.


Cytosolic bacterial pathogens activate TLR pathways in tumors that synergistically enhance STING agonist cancer therapies.

Danielson M, Nicolai C, Vo T, Wolf N, Burke T bioRxiv. 2024; .

PMID: 38352567 PMC: 10862861. DOI: 10.1101/2024.01.30.578087.


TRIM32 reduced the recruitment of innate immune cells and the killing capacity of Listeria monocytogenes by inhibiting secretion of chemokines.

OuYang X, Liu P, Zheng Y, Jiang H, Lv Q, Huang W Gut Pathog. 2023; 15(1):32.

PMID: 37415157 PMC: 10324126. DOI: 10.1186/s13099-023-00558-9.


Identification of genetic elements required for growth under limited nutrient conditions and virulence by a screening of transposon insertion library.

Narayanan L, Ozdemir O, Alugubelly N, Ramachandran R, Banes M, Lawrence M Front Microbiol. 2022; 13:1007657.

PMID: 36312968 PMC: 9608667. DOI: 10.3389/fmicb.2022.1007657.